Novartis Releases Positive Results from Postmarket Study of Migraine Drug

Novartis has announced that its approved migraine drug Aimovig (erenumab) has met its primary and secondary endpoints in a postmarket surveillance trial.

The study of 777 participants compared Aimovig and the anticonvulsant topiramate in patients suffering from chronic migraines. Those taking Aimovig saw a 50 percent reduction in monthly migraine days and a lower rate of treatment discontinuation, Novartis said.

Aimovig was approved by the FDA in May 2018 and received a marketing authorization from the European Medicines Agency in July 2018.